Jun 02, 2025
Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Jan 27, 2025
Sapience Therapeutics Presents ST316 Phase 1 Dose Escalation Data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Dec 19, 2024
Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class b-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)
Nov 09, 2024
Sapience Therapeutics Presents Clinical Data on Two Lead Programs, Including ST101 Oral Presentation, at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Nov 07, 2024
Sapience Therapeutics Announces Participation at the Jefferies London Healthcare Conference
Oct 08, 2024
Sapience Therapeutics Announces Multiple Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
Oct 01, 2024
Sapience Therapeutics Enrolls First Patient in Phase 2 Study of ST316, a First-in-Class b-catenin Antagonist, in Colorectal Cancer
Sep 09, 2024
Sapience Therapeutics to Participate at UBS Biotechnology Private Company Virtual Symposium
Jun 01, 2024
Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
May 23, 2024
Sapience Therapeutics to Showcase Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024
Apr 24, 2024
Sapience Therapeutics Announces Oral Presentation at the Upcoming 2024 ASCO Annual Meeting Featuring ST101 Phase 2 Results in GBM
Apr 08, 2024
Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Apr 03, 2024
Sapience Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Mar 05, 2024
Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Feb 13, 2024
Sapience Therapeutics to Present at the 2024 BIO CEO & Investor Conference